Resolution Chemicals sought revocation of the Supplementary Protection Certificate SPC/GB02/049 for escitalopram in the name of Lundbeck, on the grounds of the alleged invalidity of the basic patent on which the SPC is based.
Sir Terence Etherton, Hallett, Sharp LJJ
[2013] EWCA Civ 1515, [2014] 1 WLR 1943, [2013] WLR(D) 453
Bailii, WLRD
England and Wales
Updated: 22 June 2021; Ref: scu.518416 br>